Stockreport

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Candel Therapeutics, Inc.  (CADL) 
PDF Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase [Read more]